Due to a national outage, you must download a new savings card to use at your pharmacy. Learn more about this issue.

patient discussing Basaglar injection with doctor

Models used for illustrative purposes only. Not an actual patient and HCP.

First times can be challenging.

A patient’s first experience with a basal insulin is no exception.

In patients with type 1 diabetes, BASAGLAR must be used concomitantly with short-acting insulin.¹

INDICATION

BASAGLAR is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

LIMITATION OF USE

BASAGLAR is not recommended for the treatment of diabetic ketoacidosis.

SELECT IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

BASAGLAR is contraindicated during episodes of hypoglycemia, and in patients with hypersensitivity to insulin glargine or any of the excipients in BASAGLAR.

Consider the ABCs of BASAGLAR^® (insulin glargine) injection 100 units/mL

Available resources designed to be simple

And help your patients accept, start, and stay on basal insulin

Learn more about available resources

Backed by savings and support

Lilly is committed to helping people with diabetes access affordable medicines.

Learn more about the Lilly Insulin Affordability Program

Through the Lilly Insulin Value Program, all Lilly insulins are available for $35 a month whether patients have commercial insurance or no insurance.^*

These savings cover all Lilly insulins.

^*Terms and conditions apply. At retail pharmacies. Government restrictions exclude people enrolled in federal government insurance programs from Lilly's $35 solutions. But federal law provides that Medicare Part D beneficiaries also pay no more than $35 per month for insulin.

Terms, Conditions and Limitations apply to the Insulin Value Savings Card. Click on the following sections for details.

By using the Lilly Insulin Value Cash Savings Card Program (“Card”), you attest that you meet the eligibility criteria, and you agree to comply with the terms and conditions described below:

Card Eligibility:

You have been prescribed one of the following Lilly Insulin Value products (“Covered Insulin”) consistent with FDA approved product labeling: BASAGLAR^® KwikPen^® (insulin glargine) injection (100 units/mL), BASAGLAR ^® Tempo Pen^®, Humalog^® U-100 cartridge (insulin lispro) injection (100 units per mL), Humalog^® U-100 KwikPen^®, Humalog^® U-100 vial (10 mL), Humalog^® Junior KwikPen^®, Humalog^® U-200 KwikPen^®, Humalog^® Mix50/50^™ KwikPen^® (insulin lispro protamine and insulin lispro) injectable suspension (100 units per mL), Humalog^® Mix50/50^™ vial (10 mL), Humalog^® Mix75/25^™ KwikPen^®(insulin lispro protamine and insulin lispro) injectable suspension (100 units per mL), Humalog^® Mix75/25^™ vial (10 mL), Humalog^® Tempo Pen^®, Humulin^® N KwikPen^®(insulin isophane human) injectable suspension (100 units per mL) , Humulin^® N vial (10 mL), Humulin^® 70/30 KwikPen^® (insulin isophane human and insulin human) injectable suspension (100 units per mL) , Humulin^® 70/30 vial (10 mL), Humulin^® R (insulin human) injection (10 mL), Humulin^® R U-500 KwikPen^® (insulin human) injection (500 units/mL), Humulin R U-500 vial, Insulin Lispro KwikPen^® injection (100 units per mL), Insulin Lispro injection vial (10mL), Insulin Lispro Junior KwikPen^® injection, Insulin Lispro Protamine and Insulin Lispro Mix75/25^™ KwikPen^® Injectable Suspension, Lyumjev^® KwikPen^® (insulin lispro-aabc) injection (100 units/mL), Lyumjev^® U-200 KwikPen^®, Lyumjev^® U-100 vial (10 mL), Lyumjev^® Tempo Pen^®, and REZVOGLAR™ KwikPen (insulin glargine-aglr) injection (100 units/mL).
You are not enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE^®/CHAMPUS, or any state prescription drug assistance program.
You are a resident of the United States or a United States Territory (Puerto Rico, Guam, U.S. Virgin Islands, Northern Mariana Islands, American Samoa)
You are 18 years of age or older

Card Terms and Conditions
You must have a prescription consistent with FDA-approved product labeling to pay as little as $35 for a 1-month prescription fill of your Covered Insulin. Month is defined as 30-days. Card savings are subject to a maximum monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges per prescription fill, up to a maximum of 14 prescription fills per calendar year for each Covered Insulin. Subject to Lilly USA, LLC’s (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason, Card expires and savings end on 12/31/2024.

Additional Program Terms and Conditions
If you have an insurance plan that is participating in an alternate funding program (“AFP”) (examples include, but are not limited to, ImpaxRX, Payer Matrix, SHARx, Script Sourcing, and Paydhealth) that requires you to apply to the Lilly Insulin Value Cash Savings Card Program or otherwise pursue specialty drug prescription coverage through an alternate funding vendor as a condition of, requirement for, or prerequisite to coverage of your Covered Insulin, you are not eligible for and are prohibited from using the Lilly Insulin Value Cash Savings Card Program. AFPs include programs where coverage, reimbursement, or patient out of pocket costs for a product in some way vary based on the availability of a manufacturer co-pay program. AFPs may modify, delay, deny, restrict, or withhold insurance benefits or coverage from patients, or exclude Lilly products from coverage contingent upon a member's use of Lilly Insulin Value Cash Savings Card Program. You agree to inform Lilly Insulin Value Cash Savings Card Program if you are or become a member of such an alternative funding program. You are responsible for any applicable taxes, fees, and any amount that exceeds the monthly or annual maximum Card savings. Monthly and annual maximum savings are set at Lilly's sole and absolute discretion and may be changed with or without notice at any time for any reason. At its sole discretion and with or without notice, Lilly may reduce, eliminate, or otherwise modify the Card savings for any reason including but not limited to if your commercial drug insurance plan imposes additional requirements which limits or prevents you from receiving coverage for your Covered Insulin, only allows partial coverage for your Covered Insulin, removes coverage for your Covered Insulin and requires you to utilize the Card, does not provide a material level of financial assistance for the cost of your Covered Insulin, or does not apply Card payments to satisfy your co-payment, deductible, or coinsurance for your Covered Insulin. Card savings are not valid for: Massachusetts residents if an AB-rated generic equivalent is available; California residents if an FDA-approved therapeutic equivalent is available. You must meet the Card eligibility criteria, terms and conditions every time you use the Card. Card activation is required. No party may seek reimbursement from your health insurance, any third party, or any health savings, flexible spending, or other healthcare reimbursement accounts, for any amount of the savings received through the Card. Card savings cannot be combined or utilized with any other program, discount, discount card, cash discount card, coupon, incentive, or similar offer involving your Covered Insulin. You agree that this Card savings is intended solely for the benefit of you, the patient, and that the Card benefits are nontransferable. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase, or trade, or to counterfeit the Card. The Card is not insurance. Lilly has the sole right to interpret and apply Card eligibility criteria, and terms and conditions. Card eligibility, and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. Eligibility criteria, and terms and conditions for the Lilly Insulin Value Cash Savings Card Program may change from time to time; the most current version can be found at https://www.insulinaffordability.com. You may be required to obtain a new Card, including if any Card terms and conditions have been terminated, rescinded, revoked, or amended by Lilly. Card void where prohibited by law. Subject to Lilly’s right to terminate, rescind, revoke or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason, the Card expires and savings end on 12/31/2024.

By using the Lilly Insulin Value Savings Card Program (“Card”), you attest that you meet the eligibility criteria, and you agree to comply with the terms and conditions described below:

Card Eligibility:

You have been prescribed one of the following Lilly Insulin Value products (“Covered Insulin”) consistent with FDA approved product labeling: BASAGLAR^® KwikPen^® (insulin glargine) injection (100 units/mL), BASAGLAR ^® Tempo Pen^®, Humalog^® U-100 cartridge (insulin lispro) injection (100 units per mL), Humalog^® U-100 KwikPen^®, Humalog^® U-100 vial (10 mL), Humalog^® Junior KwikPen^®, Humalog^® U-200 KwikPen^®, Humalog^® Mix50/50^™ KwikPen^® (insulin lispro protamine and insulin lispro) injectable suspension (100 units per mL), Humalog^® Mix50/50^™ vial (10 mL), Humalog^® Mix75/25^™ KwikPen^®(insulin lispro protamine and insulin lispro) injectable suspension (100 units per mL), Humalog^® Mix75/25^™ vial (10 mL), Humalog^® Tempo Pen^®, Humulin^® N KwikPen^®(insulin isophane human) injectable suspension (100 units per mL) , Humulin^® N vial (10 mL), Humulin^® 70/30 KwikPen^® (insulin isophane human and insulin human) injectable suspension (100 units per mL) , Humulin^® 70/30 vial (10 mL), Humulin^® R (insulin human) injection (10 mL), Humulin^® R U-500 KwikPen^® (insulin human) injection (500 units/mL), Humulin R U-500 vial, Insulin Lispro KwikPen^® injection (100 units per mL), Insulin Lispro injection vial (10mL), Insulin Lispro Junior KwikPen^® injection, Insulin Lispro Protamine and Insulin Lispro Mix75/25^™ KwikPen^® Injectable Suspension, Lyumjev^® KwikPen^® (insulin lispro-aabc) injection (100 units/mL), Lyumjev^® U-200 KwikPen^®, Lyumjev^® U-100 vial (10 mL), Lyumjev^® Tempo Pen^®, and REZVOGLAR^™ KwikPen (insulin glargine-aglr) injection (100 units/mL).
You are enrolled in a commercial drug insurance plan
You are not enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE^®/CHAMPUS, or any state prescription drug assistance program.
You are a resident of the United States or a United States Territory (Puerto Rico, Guam, U.S. Virgin Islands, Northern Mariana Islands, American Samoa)
You are 18 years of age or older

Card Terms and Conditions

For patients with commercial drug insurance coverage for your Covered Insulin: You must have commercial drug insurance that covers your Covered Insulin and a prescription consistent with FDA-approved product labeling to pay as little as $35 for a 1-month prescription fill of your Covered Insulin. Month is defined as 30-days. Card savings are subject to a maximum monthly savings of up to $3,000 per prescription fill of each Covered Insulin and separate maximum annual savings of up to $16,000 per calendar year for each Covered Insulin. Card may be used for a maximum of up to 16 prescription fills per calendar year for each Covered Insulin. Subject to Lilly USA, LLC’s (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason, Card expires and savings end on 12/31/2024.

For patients with commercial drug insurance who do not have coverage for your Covered Insulin: You must have commercial drug insurance that does not cover your Covered Insulin and a prescription consistent with FDA-approved product labeling to pay as little as $35 for a 1-month prescription fill of your Covered Insulin. Month is defined as 30-days. Card savings are subject to a maximum monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges per prescription fill, up to a maximum of 14 prescription fills per calendar year for each Covered Insulin. Subject to Lilly’s right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason, Card expires and savings end on 12/31/2024.

Additional Program Terms and Conditions
If you have an insurance plan that is participating in an alternate funding program (“AFP”) (examples include, but are not limited to, ImpaxRX, Payer Matrix, SHARx, Script Sourcing, and Paydhealth) that requires you to apply to the Lilly Insulin Value Savings Card Program or otherwise pursue specialty drug prescription coverage through an alternate funding vendor as a condition of, requirement for, or prerequisite to coverage of your Covered Insulin, you are not eligible for and are prohibited from using the Lilly Insulin Value Savings Card Program. AFPs include programs where coverage, reimbursement, or patient out of pocket costs for a product in some way vary based on the availability of a manufacturer co-pay program. AFPs may modify, delay, deny, restrict, or withhold insurance benefits or coverage from patients, or exclude Lilly products from coverage contingent upon a member’s use of Lilly Insulin Value Savings Card Program. You agree to inform Lilly Insulin Value Savings Card Program if you are or become a member of such an alternative funding program. You are responsible for any applicable taxes, fees, and any amount that exceeds the monthly or annual maximum Card savings. Monthly and annual maximum savings are set at Lilly’s sole and absolute discretion and may be changed with or without notice at any time for any reason. At its sole discretion and with or without notice, Lilly may reduce, eliminate, or otherwise modify the Card savings for any reason, including but not limited to if your commercial drug insurance plan imposes additional requirements which limits or prevents you from receiving coverage for your Covered Insulin, only allows partial coverage for your Covered Insulin, removes coverage for your Covered Insulin and requires you to utilize the Card, does not provide a material level of financial assistance for the cost of your Covered Insulin, or does not apply Card payments to satisfy your co-payment, deductible, or coinsurance for your Covered Insulin. Card savings are not valid for: Massachusetts residents if an AB-rated generic equivalent is available; California residents if an FDA-approved therapeutic equivalent is available. You must meet the Card eligibility criteria, terms and conditions every time you use the Card. Card activation is required. No party may seek reimbursement from your health insurance, any third party, or any health savings, flexible spending, or other healthcare reimbursement accounts, for any amount of the savings received through the Card. By utilizing the Card, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you will notify your Insurance Carrier of your redemption of the Card. Card savings cannot be combined or utilized with any other program, discount, discount card, cash discount card, coupon, incentive, or similar offer involving your Covered Insulin. You agree that this Card savings is intended solely for the benefit of you, the patient, and that the Card benefits are nontransferable. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase, or trade, or to counterfeit the Card. The Card is not insurance. Lilly has the sole right to interpret and apply Card eligibility criteria, and terms and conditions. Card eligibility, and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. Eligibility criteria, and terms and conditions for the Lilly Insulin Value Savings Card Program may change from time to time; the most current version can be found at https://www.insulinaffordability.com. You may be required to obtain a new Card, including if any Card terms and conditions have been terminated, rescinded, revoked, or amended by Lilly. Card void where prohibited by law. Subject to Lilly’s right to terminate, rescind, revoke or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason, the Card expires and savings end on 12/31/2024.

SELECT IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

BASAGLAR prefilled pens must never be shared between patients, even if the needle is changed. Sharing poses a risk of transmission of blood borne pathogens.

Comparable A1C reduction

BASAGLAR demonstrated noninferiority to Lantus^® (insulin glargine) as measured by A1C reduction in adult patients with type 2 diabetes.^1,2

BASAGLAR vs Lantus plus 2 or more OAMs (24 weeks)

A1C reduction from baseline
- Noninferiority demonstrated: A1C reduction from baseline at 24 weeks^1,2
- BASAGLAR (n=376^‡; baseline A1C: 8.35%): 1.3%
- Lantus (n=380^‡; baseline A1C: 8.31%): 1.3%
- Difference of 0.052% (95% CI -0.070 to 0.175)
- The primary efficacy outcome was to test the noninferiority (0.4% and then 0.3% margin) of BASAGLAR to Lantus, as measured by change in A1C from baseline to 24 weeks

^‡Three patients randomized to BASAGLAR did not receive study drug and were not included in the full analysis set. Observed A1C data at 24 weeks were available from 331 (88%) and 329 (87%) patients randomized to the BASAGLAR and Lantus groups, respectively.

See full trial design information below.

Type 2 diabetes: Adverse reactions occurring in ≥5% of adult patients treated with BASAGLAR or Lantus over 24 weeks of treatment^1,3

The trial was not designed to evaluate the relative safety between BASAGLAR and Lantus, and comparator adverse event rates are not an adequate basis for comparison of rates between the products.

Adverse Events	BASAGLAR + OAMs (n=376)	Lantus + OAMs (n=380)
Adverse Events Infection^§\|\|	BASAGLAR + OAMs (n=376): 17%	Lantus + OAMs (n=380): 16%
Adverse Events Nasopharyngitis	BASAGLAR + OAMs (n=376): 6%	Lantus + OAMs (n=380): 6%
Adverse Events Upper respiratory tract infection	BASAGLAR + OAMs (n=376): 5%	Lantus + OAMs (n=380): 4%

^§ Infections other than nasopharyngitis or upper respiratory tract infection.

^||Infections were a category of treatment-emergent adverse events that were reported during the 24-week trial and included events such as influenza, urinary tract infection, bronchitis, gastroenteritis, and sinusitis. Excluded were nasopharyngitis and upper respiratory tract infection.⁴

Hypoglycemia was the most commonly observed adverse reaction in patients using insulin, including BASAGLAR. Hypoglycemia was defined as blood glucose ≤3.9 mmol/L (≤70 mg/dL) or a sign or symptom associated with hypoglycemia. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death.

CI=confidence interval; OAMs=oral anti-diabetic medications.

Learn more about BASAGLAR Efficacy and Safety

Trial design: 24-week phase 3, randomized, double-blind trial of 756 patients with type 2 diabetes who were either insulin-naive and failed to achieve adequate glycemic control on at least 2 OAMs, or were already on Lantus along with 2 or more OAMs with adequate or inadequate glycemic control. The primary endpoint was noninferiority of BASAGLAR to Lantus as measured by change in A1C from baseline at 24 weeks.^1,2

The starting dose for all insulin-naive patients was 10 U/day, while patients entering the study on Lantus were randomized to either BASAGLAR or Lantus at a dose equivalent to their prestudy Lantus dose; BASAGLAR and Lantus titration was patient-driven based on self-measured fasting plasma glucose with a target of ≤100 mg/dL.²

SELECT IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Changes in insulin strength, manufacturer, type, injection site, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Any changes in insulin regimen should be made cautiously and only under close medical supervision, and the frequency of blood glucose monitoring should be increased. Due to reports of hypoglycemia and hyperglycemia, advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor blood glucose. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.

References:

BASAGLAR. Prescribing Information. Lilly USA, LLC.
Rosenstock J, Hollander P, Bhargava A, et al. Diabetes Obes Metab. 2015;17:734-741.
Data on file, Lilly USA, LLC. BAS20160408A.
Data on file, Lilly USA, LLC. BAS20160811B.

IMPORTANT SAFETY INFORMATION

Contraindications -

BASAGLAR is contraindicated during episodes of hypoglycemia, and in patients with hypersensitivity to insulin glargine or any of the excipients in BASAGLAR.

Warnings and Precautions

BASAGLAR prefilled pens must never be shared between patients, even if the needle is changed. Sharing poses a risk of transmission of blood borne pathogens.

Hypoglycemia is the most common adverse reaction associated with insulins, including BASAGLAR. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death.

Accidental mix-ups between insulin products have been reported. To avoid hypoglycemia due to medication errors between BASAGLAR and other insulins, instruct patients to always check the insulin label before each injection.

Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulins, including BASAGLAR. If hypersensitivity reactions occur, discontinue BASAGLAR; treat per standard of care and monitor until symptoms and signs resolve. BASAGLAR is contraindicated in patients who have had hypersensitivity reactions to insulin glargine or one of the excipients.

All insulins, including BASAGLAR, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated.

Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

Adverse Reactions

Adverse reactions commonly (>5%) associated with insulin glargine products are: hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, rash, edema, and weight gain.

Drug Interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose.

The risk of hypoglycemia may increase when antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics are co-administered with BASAGLAR.

The blood glucose lowering effect of BASAGLAR may decrease when co-administered with atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. The blood glucose lowering effect of BASAGLAR may increase or decrease when co-administered with alcohol, beta-blockers, clonidine, lithium salts, and pentamidine.

The signs and symptoms of hypoglycemia may be blunted when beta-blockers, clonidine, guanethidine, and reserpine are co-administered with BASAGLAR.

BV HCP ISI 14SEP2022

For more information, please see accompanying Full Prescribing Information and Patient Information. Please see Instructions for Use.

INDICATION

BASAGLAR is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

Limitations of Use: BASAGLAR is not recommended for the treatment of diabetic ketoacidosis.

First times can be challenging.

A patient’s first experience with a basal insulin is no exception.

In patients with type 1 diabetes, BASAGLAR must be used concomitantly with short-acting insulin.1

Consider the ABCs of BASAGLAR® (insulin glargine) injection 100 units/mL

Available resources designed to be simple

Backed by savings and support

Expand accordion Cash Savings Card Terms and Conditions

Expand accordion Commercial Savings Card Terms and Conditions

Comparable A1C reduction

IMPORTANT SAFETY INFORMATION

Contraindications -

Warnings and Precautions

Adverse Reactions

Drug Interactions

INDICATION

In patients with type 1 diabetes, BASAGLAR must be used concomitantly with short-acting insulin.¹

Consider the ABCs of BASAGLAR^® (insulin glargine) injection 100 units/mL